TK011: Prospective, non-interventional, post-authorisation safety study (PASS) of Zalmoxis prescribed in patients undergoing haploidentical hematopoietic stem cell transplantation for high-risk hematological malignancies First published 20/12/2016 Last updated 28/03/2022 EU PAS number:EUPAS16894 Study Planned